MS Study Identifies Patients at Risk of Disease Surge After Halting Gilenya

I have cancer. Don’t tell me you’re sorry 
February 28, 2018
Rheumatoid Arthritis Symptoms Benefit From Essential Oils and Aromatherapy
March 1, 2018
Show all

MS Study Identifies Patients at Risk of Disease Surge After Halting Gilenya

Discontinuing treatment with Gilenya can make disease activity increase dramatically.

Multiple sclerosis patients with high relapse rates but less physical impairment before starting on  Novartis’ Gilenya (fingolimod) are likely to experience a surge in disease activity if they stop the treatment, researchers in Turkey report.

The study, which dealt with patients with relapsing forms of MS, referred to the surge as “severe disease reactivation,” or SDR.

Researchers published their article, “Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation,” in the journal The Neurologist.

Studies have shown that Gilenya, which the U.S. Food and Drug Administration approved in 2010, can benefit adults with relapsing MS. It reduces annualized relapse rates and prevents more brain lesions from forming, compared with standard interferon treatments. Lesions are damaged nerve cell areas.

Despite its benefits, Gilenya is not recommended for patients with heart or liver problems, low levels of white blood cells, severe herpes virus infections or other infections. Also, patients who do not respond to Gilenya and women who are planning to become pregnant are advised to stop the treatment.

Discontinuing Gilenya can lead to a return to pretreatment disease activity, or severe disease reactivation, in some patients. It is unclear why this happens and why it affects only some patients.

To better understand what risk factors could be associated with reactivation, a team at Istanbul University compared the demographic and disease features of patients who developed SDR after stopping treatment with Gilenya.

SDR was defined as including these elements within 6 months of Gilenya discontinuation:

  • more than 5 gadolinium-enhanced lesions or a tumefactive demyelinating lesion detectable by magnetic resonance imaging,
  • the disease progressing to the point that additional treatment with methylprednisolone or plasma exchange was required, and
  • progressive physical disability reflected by a 1-point or more increase in patients’ scores on the Expanded Disability Status Scale, or EDSS,

Read full article: MS Study Identifies Patients at Risk of Disease Surge After Halting Gilenya

Read Full Article: MS Study Identifies Patients at Risk of Disease Surge After Halting Gilenya 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.